‘We are very worked up about this 1st publication that demonstrates the prospect of a noninvasive test that is highly accurate, cost scalable and efficient.’.. Aria’s noninvasive test more effective in detecting Trisomy 18 & 21 Aria Diagnostics , a molecular diagnostics business, announced publication of data helping a directed today, noninvasive approach to cell-free DNA analysis in maternal blood for evaluation of two common fetal trisomies linked to genetic disorders. The total results, assessing the detection of Trisomy 21 and Trisomy 18 , had been published on-line at ‘Our capability to recognize pregnancies at high risk for chromosomal abnormalities offers significantly improved during the last decade, but has limitations in precision and price still,’ stated Dr.‘Expansion into China can be a business concern for Amgen, and opening this R&D middle is another apparent and important step of progress in Amgen’s dedication to the China marketplace,’ Sean E. Harper, M.D., evp of research and development at Amgen, stated in a statement. ShanghaiTech is certainly jointly sponsored and structured by the Shanghai municipal government, which is in charge of its operation, and the Chinese Academy of Sciences . Amgen’s partnership with ShanghaiTech is the company’s 5th initiative announced this season toward shoring up its presence in China and the others of Asia. Speaking on Amgen’s most recent quarterly earnings call on July 30, Robert A. Bradway, Amgen’s chairman and CEO, told analysts the ongoing company expects Vectibix to end up being ‘our first new product for China in the 2015 timeframe.’ ‘We try to address unmet medical requirements that are particularly relevant for sufferers in China,’ added Mingqiang Zhang, Ph.D., Amgen’s vp of China study and development.